Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic.
First Faculty of Medicine, Charles University, Prague 2, Czech Republic.
Prostate. 2019 Feb;79(2):126-139. doi: 10.1002/pros.23717. Epub 2018 Sep 5.
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is an important diagnostic and therapeutic target in prostate cancer. PSMA/GCPII is also expressed in many healthy tissues, but its function has only been established in the brain and small intestine. Several research groups have attempted to produce PSMA/GCPII-deficient mice to study the physiological role of PSMA/GCPII in detail. The outcomes of these studies differ dramatically, ranging from embryonic lethality to production of viable PSMA/GCPII-deficient mice without any obvious phenotype.
We produced PSMA/GCPII-deficient mice (hereafter also referred as Folh1 mice) by TALEN-mediated mutagenesis on a C57BL/6NCrl background. Using Western blot and an enzyme activity assay, we confirmed the absence of PSMA/GCPII in our Folh1 mice. We performed anatomical and histopathological examination of selected tissues with a focus on urogenital system. We also examined the PSMA/GCPII expression profile within the mouse urogenital system using an enzyme activity assay and confirmed the presence of PSMA/GCPII in selected tissues by immunohistochemistry.
Our Folh1 mice are viable, breed normally, and do not show any obvious phenotype. Nevertheless, aged Folh1 mice of 69-72 weeks exhibit seminal vesicle dilation, which is caused by accumulation of luminal fluid. This phenotype was also observed in Folh1 mice; the overall difference between our three cohorts (Folh1 , Folh1 , and Folh1 ) was highly significant (P < 0.002). Of all studied tissues of the mouse urogenital system, only the epididymis appeared to have a physiologically relevant level of PSMA/GCPII expression. Additional experiments demonstrated that PSMA/GCPII is also present in the human epididymis.
In this study, we provide the first evidence characterizing the reproductive tissue phenotype of PSMA/GCPII-deficient mice. These findings will help lay the groundwork for future studies to reveal PSMA/GCPII function in human reproduction.
前列腺特异性膜抗原(PSMA),也称为谷氨酸羧肽酶 II(GCPII),是前列腺癌的重要诊断和治疗靶点。PSMA/GCPII 也在许多健康组织中表达,但它的功能仅在大脑和小肠中得到证实。几个研究小组试图产生 PSMA/GCPII 缺陷小鼠,以详细研究 PSMA/GCPII 的生理作用。这些研究的结果差异很大,从胚胎致死到产生无明显表型的存活 PSMA/GCPII 缺陷小鼠不等。
我们通过在 C57BL/6NCrl 背景下使用 TALEN 介导的诱变产生 PSMA/GCPII 缺陷小鼠(以下简称 Folh1 小鼠)。使用 Western blot 和酶活性测定,我们证实我们的 Folh1 小鼠中缺乏 PSMA/GCPII。我们对选定的组织进行解剖和组织病理学检查,重点是尿生殖系统。我们还使用酶活性测定在小鼠尿生殖系统中检查 PSMA/GCPII 的表达谱,并通过免疫组织化学证实 PSMA/GCPII 在选定组织中的存在。
我们的 Folh1 小鼠具有活力,繁殖正常,并且没有表现出任何明显的表型。然而,69-72 周龄的老年 Folh1 小鼠出现精囊扩张,这是由于管腔液体积聚所致。这种表型也在 Folh1 小鼠中观察到;我们的三个队列(Folh1 、Folh1 和 Folh1 )之间的总体差异具有高度显著性(P<0.002)。在研究的所有小鼠尿生殖系统组织中,只有附睾似乎具有与生理相关的 PSMA/GCPII 表达水平。进一步的实验表明,PSMA/GCPII 也存在于人类附睾中。
在这项研究中,我们首次提供了特征描述 PSMA/GCPII 缺陷小鼠生殖组织表型的证据。这些发现将为未来研究揭示 PSMA/GCPII 在人类生殖中的功能奠定基础。